Korro Bio reported a Q2 2025 net loss of $25.8M on $1.46M in collaboration revenue, driven by higher R&D and G&A expenses. Cash and marketable securities ended at $119.6M, expected to support operations into 2027.

Korro Bio, Inc. reported a net loss of $23.387 million for the first quarter of 2025, an increase from the $19.557 million net loss in the same period last year. The company generated $2.550 million in collaboration revenue, compared to no revenue in the prior year. Operating expenses increased significantly, primarily driven by higher research and development costs.

Korro Bio initiated its Phase 1/2a REWRITE clinical study for KRRO-110, received Orphan Drug Designation for AATD, and strengthened its financial position with $163.1 million in cash, cash equivalents, and marketable securities, extending its cash runway into the second half of 2026.

Korro Bio reported its third quarter 2024 financial results, highlighting a regulatory filing submission, the formation of a Clinical Advisory Board, and a collaboration agreement with Novo Nordisk. The company ended the quarter with $169.1 million in cash, cash equivalents, and marketable securities, expecting this to fund operations into the second half of 2026.

Korro Bio reported a net loss of $21.8 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $187.8 million as of June 30, 2024, providing a cash runway into the second half of 2026.

Korro Bio reported its Q1 2024 financial results, highlighting a strengthened cash position with a $70.0 million private placement, progress towards regulatory filing for KRRO-110, and the appointment of Dr. Kemi Olugemo as Chief Medical Officer. Cash and cash equivalents were $138.8 million as of March 31, 2024 and the company anticipates a regulatory filing for KRRO-110 in AATD in the second half of 2024.

Korro Bio reported a strong cash position of $166.1 million and reiterated progress on KRRO-110 and other pipeline candidates.

Korro Bio completed its merger with Frequency Therapeutics and a $117 million private placement. The combined company, operating as Korro Bio, is expected to have approximately $170 million in cash to fund operations into 2026, advancing its RNA editing programs.

Frequency Therapeutics reported a net loss of $10.8 million for the second quarter of 2023, compared to a net loss of $21.3 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $46.5 million as of June 30, 2023. Frequency Therapeutics entered into a definitive merger agreement with Korro Bio, Inc. and continues to explore strategic alternatives for its pre-clinical remyelination program for multiple sclerosis.

Frequency Therapeutics reported a net loss of $19.5 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $66.7 million as of March 31, 2023, and they believe their restructuring activities will extend their runway into 2025 and enable them to complete a first clinical trial of their MS Program.

Frequency Therapeutics reported a net loss of $17.4 million for the fourth quarter ended December 31, 2022, compared to a net loss of $21.5 million for the comparable period in 2021. The company's cash position as of December 31, 2022, was $83.1 million. Frequency is focusing on its program to induce remyelination for individuals living with multiple sclerosis and expects to initiate clinical development in the first half of 2024.

Frequency Therapeutics reported its Q3 2022 financial results, including a cash position of $99.3 million. The company completed enrollment for the Phase 2b study of FX-322 and is on track for a Q4 clinical trial start of FX-345. A multiple sclerosis remyelination program candidate was advanced to IND-enabling studies.